Disappointing Results of Dexpramipexole Trial in ALS (Podcast)

Douglas Kerr of the biotech firm Biogen Idec spoke with MDA Executive Vice President of Research and Medical Director Valerie Cwik on Jan. 11, 2013, about the company’s recent decision to stop development of dexpramipexole for amyotrophic lateral sclerosis, after the drug showed no efficacy in a 943-person, phase 3 clinical trial. This podcast complements Podcast: What Happened with Dexpramipexole for ALS? (ALS News Online, Jan. 15, 2013).

No votes yet